Evidence map›Paper›PMID 35428779›Full record

ArticleScientific reports2022

HiIDDD: a high-throughput imaging pipeline for the quantitative detection of DNA damage in primary human immune cells.

Kelsey Gallant, Arsun Bektas, Mary Kaileh, Ana Lustig, Luigi Ferrucci, Gianluca Pegoraro, Tom Misteli

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. 3D genome organization.Scientific reports · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kelsey GallantNational Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Arsun BektasNational Institute On Aging, NIH, Baltimore, MD, 21224, USA.
Mary KailehNational Institute On Aging, NIH, Baltimore, MD, 21224, USA.
Ana LustigNational Institute On Aging, NIH, Baltimore, MD, 21224, USA.
Luigi FerrucciNational Institute On Aging, NIH, Baltimore, MD, 21224, USA.ORCID 0000-0002-6273-1613
Gianluca PegoraroNational Cancer Institute, NIH, Bethesda, MD, 20892, USA.ORCID 0000-0003-2843-9464
Tom MisteliNational Cancer Institute, NIH, Bethesda, MD, 20892, USA. mistelit@mail.nih.gov.ORCID 0000-0003-3530-3020
National Institute on Aging · USNational Cancer Institute · USNational Institutes of Health · US

Funding

Nuclear Architecture and DiseaseZIABC010309 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MISTELI, THOMAS A · 2009 to 2025
$39.8M
HiTIF Microscopy Core FacilityZICBC011567 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PEGORARO, GIANLUCA · 2014 to 2025
$15.8M
GESTALT-Genetic and Epigenetic Signatures of Translational Aging Laboratory TestingZIAAG000996 · NIA · NATIONAL INSTITUTE ON AGING · PI FERRUCCI, LUIGI · 2015 to 2025
$7.6M
6 · The paper itself

Abstract

DNA damage is a prominent biomarker for numerous diseases, including cancer, as well as for the aging process. Detection of DNA damage routinely relies on traditional microscopy or cytometric methods. However, these techniques are typically of limited throughput and are not ideally suited for large-scale longitudinal and population studies that require analysis of large sample sets. We have developed HiIDDD (High-throughput Immune cell DNA Damage Detection), a robust, quantitative and single-cell assay that measures DNA damage by high-throughput imaging using the two major DNA damage markers 53BP1 and [Formula: see text]-H2AX. We demonstrate sensitive detection with low inter-assay variability of DNA damage in various types of freshly isolated and cryopreserved primary human immune cells, including CD4 + and CD8 + T cells, B cells and monocytes. As proof of principle, we demonstrate parallel batch processing of several immune cell types from multiple donors. We find common patterns of DNA damage in multiple immune cell types of donors of varying ages, suggesting that immune cell properties are specific to individuals. These results establish a novel high-throughput assay for the evaluation of DNA damage in large-scale studies.

Indexed as

DNA DamageHigh-Throughput Screening AssaysBiological AssayCryopreservationDiagnostic ImagingHumans

Identifiers

PMID35428779
PMCPMC9022135
OpenAlexW4225965657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.